Bedrijfsoverzicht
Emergent BioSolutions Inc. is a life sciences enterprise dedicated to delivering preparedness and response solutions for public health threats resulting from accidents, intentional acts, or natural occurrences across the United States, Canada, and international markets. The company operates within the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, a classification that defines its focus on producing specialized pharmaceutical products rather than mass-market generics. In terms of scale, the entity manages a market capitalization of $412.10M, generates annual revenue of $742.90M, and employs a workforce of 900 individuals. These valuation and revenue figures indicate that while the company maintains a substantial operational footprint with nearly a thousand employees, it currently holds a relatively modest market valuation compared to large-cap healthcare peers, suggesting a mid-cap status with specific niche exposure.
Financiële gezondheid
The company's financial performance over the trailing twelve months demonstrates a revenue generation of $742.90M, resulting in a net income of $52.60M and an EBITDA of $208.90M. The significant disparity between the $742.90M in revenue and the $52.60M in net income highlights a substantial cost structure, where operating expenses and other deductions consume a large portion of top-line sales before reaching the bottom line. Despite the lower net income, the company has generated $205.39M in free cash flow, which indicates a robust ability to convert earnings into actual cash available for operational flexibility, debt repayment, or potential strategic investments. The margin profile reveals distinct operational characteristics, with a gross margin of 49.4% reflecting strong pricing power or manufacturing efficiency on product sales, contrasted by an operating margin of -15.2% that suggests high selling, general, and administrative expenses, while the profit margin stands at 7.1%. On the balance sheet, the company holds $205.40M in cash against $583.70M in debt, creating a leverage position evidenced by a debt-to-equity ratio of 111.69, which points to a highly leveraged structure where liabilities exceed equity. Liquidity is currently very strong, as indicated by a current ratio of 5.01, meaning the company possesses more than five times the current assets necessary to cover its short-term obligations. Return metrics further clarify management effectiveness, showing a return on equity of 10.5% and a return on assets of 5.3%, which suggests that while the company utilizes shareholder capital efficiently, the high asset base relative to net income dilutes the overall return on the total asset portfolio.
Waarderingsbeoordeling
Valuation multiples provide insight into market expectations, with the company trading at a trailing P/E ratio of 8.56 and a forward P/E of 2.66. The substantial difference between the trailing and forward P/E ratios implies that the market anticipates a significant improvement in earnings trajectory, as the forward multiple suggests future earnings are expected to be much higher relative to the current stock price. The price-to-book ratio is recorded at 0.79, indicating that the stock is trading below its book value, which suggests the market does not currently assign a premium to the company's tangible assets. Alternative valuation metrics further contextualize the price, showing a price-to-sales ratio of 0.55 and an EV/EBITDA of 3.78, both of which are low multiples that suggest the company is undervalued relative to its sales and cash-flow-generating capabilities on a discounted basis. Price action over the last year shows a 52-week high of $14.06 and a 52-week low of $4.34, providing a range within which the current price fluctuates. The beta value of 2.36 indicates that the stock price is significantly more volatile than the broader market, moving with roughly 2.36 times the intensity of market swings.
Growth & Income
Revenue growth year-over-year stands at -23.6%, while earnings growth is listed as N/A, reflecting the current contraction in the top line and the absence of reported earnings growth data for this period. Given the negative revenue growth and the lack of positive earnings growth, the company is not in a phase of expanding profitability, which complicates the sustainability of any dividend policy. As a non-dividend payer, the company currently does not distribute a dividend yield or maintain a payout ratio, effectively directing all available earnings toward reinvestment in growth initiatives, debt management, or operational expansion rather than shareholder payouts. This income profile, characterized by a complete absence of dividend distributions, aligns with a growth-oriented or restructuring strategy where capital is retained to address the recent revenue decline and leverage the low valuation multiples for potential future expansion.